Coronary Disease Management

Pharmacological Management for Event Prevention

• The European Society of Cardiology recommends aspirin 75-100 mg daily as the foundation for all patients with established coronary disease, particularly those with prior myocardial infarction or revascularization 1, 2, 3
• The American College of Cardiology suggests clopidogrel 75 mg daily as an alternative in aspirin-intolerant patients 2, 4
• Dual antiplatelet therapy (aspirin plus clopidogrel) is required for 6 months after coronary stent implantation 4
• Statins are mandatory in all patients with coronary disease to reduce major vascular events and mortality 1, 2, 3
• The European Heart Society recommends adding ezetimibe if LDL goals are not achieved with maximum tolerated statin dose 1, 2, 4
• For very high-risk patients not reaching goals on statin plus ezetimibe, add a PCSK9 inhibitor 2, 4
• ACE inhibitors or ARBs are recommended particularly when hypertension, diabetes, heart failure, or left ventricular dysfunction coexist 1, 2, 4

Pharmacological Management for Symptom Relief

• Beta-blockers are first-line for controlling heart rate and relieving angina symptoms 1, 2, 3
• Calcium channel blockers are appropriate when beta-blockers are contraindicated or poorly tolerated 1, 2, 3
• Short-acting nitrates (sublingual nitroglycerin) provide immediate relief for effort angina and should be prescribed to all patients 1, 2, 3, 4

Lifestyle Modifications

• Exercise-based cardiac rehabilitation is fundamental and significantly reduces cardiovascular mortality and morbidity while improving risk factor control 1, 2, 3, 4
• Annual influenza vaccination is recommended, especially in elderly patients, to reduce mortality risk 1, 2, 3, 4
• Psychological interventions are recommended to address depression symptoms 1, 2, 4

Revascularization Strategies

• High-risk patients with severe symptoms refractory to medical treatment require invasive coronary angiography with FFR/iFR guidance 1, 5, 4
• Coronary artery bypass grafting (CABG) is recommended for left main stenosis, significant proximal left anterior descending artery stenosis, multivessel disease, or disabling angina 6
• Percutaneous coronary intervention (PCI) is appropriate for single vessel disease or selected patients with objective evidence of ischemia 6

Special Populations

• For microvascular angina: First-line beta-blocker, second-line add long-acting nitrate 7
• For vasospastic angina: First-line calcium channel blocker, second-line add long-acting nitrate 7
• Diuretics for symptomatic patients with signs of congestion 5, 4
• Beta-blockers are essential for both angina relief and reducing morbidity/mortality in heart failure 5, 4

Monitoring and Follow-Up

• Clinical follow-up at least annually to assess symptoms, functional status, adherence to lifestyle and medical interventions, and monitor for complications 8
• Review patient response to medical therapies at 2-4 weeks after drug initiation 2, 4
• Patient education about the disease, risk factors, and treatment strategy is essential for long-term adherence 2, 3, 4

Immediate Management of Established Coronary Artery Disease (European Society of Cardiology Guidelines)

Antithrombotic and Lipid Therapy

• Aspirin 75–100 mg daily, high‑intensity statin therapy, and short‑acting nitrates should be started immediately in all patients with established coronary artery disease, together with exercise‑based cardiac rehabilitation, to reduce major vascular events and mortality. 9
• High‑intensity statin therapy must be initiated promptly in every CAD patient to lower the risk of major vascular events and death. [9][10]

Blood‑Pressure Management

• Prescribe an ACE‑inhibitor (or an ARB if ACE‑inhibitor intolerant) for CAD patients, especially when hypertension, diabetes, heart failure, or left‑ventricular dysfunction coexist. 9
• Target office systolic blood pressure 120–130 mmHg (130–140 mmHg in patients > 65 years). 9
• Never combine ACE‑inhibitors with ARBs. 9

Symptom‑Control Pharmacotherapy

• Beta‑blockers are first‑line agents for heart‑rate control and angina relief, particularly after a recent myocardial infarction. 9
• Calcium‑channel blockers are appropriate when beta‑blockers are contraindicated or poorly tolerated; they may be combined with beta‑blockers. 9
• Short‑acting nitrates (sublingual nitroglycerin) should be prescribed to all CAD patients for immediate relief of effort angina. 9

Lifestyle and Risk‑Factor Interventions

• Smoking‑cessation interventions must be implemented immediately in all CAD patients. 10

Risk Stratification and High‑Risk Features

• Left‑ventricular ejection fraction < 50 % identifies a higher‑risk subgroup. [9][11]
• High‑risk anatomical features include left‑main disease, multivessel disease with reduced LV function, multivessel disease with diabetes mellitus, and high‑risk non‑invasive ischemia testing (>10 % of LV mass ischemic). 12

Indications for Urgent Invasive Coronary Angiography

• Severe angina refractory to maximal medical therapy warrants urgent invasive coronary angiography. [12][9]
• Recurrent ischemia (recurrent chest pain or dynamic ST‑segment changes), elevated troponin levels, hemodynamic instability, or major arrhythmias (repetitive ventricular tachycardia or ventricular fibrillation) are additional urgent indications. 13

Recommendations on Revascularization Decision‑Making

• Coronary angiography should not be performed solely for risk stratification; medical therapy must be optimized before considering revascularization, except in high‑risk patients with persistent symptoms. 9
• Coronary CT angiography is not recommended as a routine follow‑up test for patients with established CAD. 9

Management of Coronary Artery Disease: Evidence‑Based Recommendations

Immediate Pharmacological Therapy

Antiplatelet Therapy

• Aspirin 75–100 mg daily should be prescribed to every patient with established coronary artery disease unless a contraindication exists. 14

Lipid‑Lowering Therapy

• Initiate high‑intensity statin therapy immediately, aiming for LDL‑cholesterol < 55 mg/dL (1.4 mmol/L) and at least a 50 % reduction from baseline. 14
• If the maximum tolerated statin dose does not achieve the LDL target, add ezetimibe. 14
• For patients still not at goal after statin + ezetimibe, add bempedoic acid. 14

Blood‑Pressure Management

• Prescribe an ACE inhibitor (or an ARB if ACE‑inhibitor intolerant) to all patients with coronary artery disease, especially when hypertension, diabetes, heart failure, or left‑ventricular dysfunction coexist. 14

Glucose‑Lowering Therapy (Diabetic Patients)

• SGLT2 inhibitors with proven cardiovascular benefit are required for patients with type 2 diabetes and coronary artery disease, irrespective of baseline or target HbA1c. 14
• In patients with coronary artery disease who are not diabetic but have overweight/obesity (BMI > 27 kg/m²), consider the GLP‑1 receptor agonist semaglutide to lower cardiovascular mortality, myocardial infarction, and stroke risk. 14

Anti‑Inflammatory Therapy

• Low‑dose colchicine 0.5 mg daily may be used in patients with atherosclerotic coronary artery disease to reduce myocardial infarction, stroke, and the need for revascularization. 14

Indications for Revascularization

• In patients with left‑ventricular ejection fraction > 35 % and functionally significant left‑main stem stenosis, coronary revascularization is mandatory to improve survival. 15
• In patients with left‑ventricular ejection fraction > 35 % and functionally significant three‑vessel disease, revascularization is mandatory to improve long‑term survival and lower cardiovascular mortality and spontaneous myocardial infarction. 15
• In patients with left‑ventricular ejection fraction > 35 % and functionally significant single‑ or two‑vessel disease involving the proximal left anterior descending artery, revascularization is mandatory to reduce long‑term cardiovascular mortality and spontaneous myocardial infarction. 15
• When angina persists despite guideline‑directed medical therapy, revascularization of functionally significant obstructive disease is required to relieve symptoms. 15
• For patients with left‑ventricular ejection fraction ≤ 35 %, the decision between revascularization and medical therapy alone should be made by a multidisciplinary Heart Team after evaluating coronary anatomy, the relationship between disease and ventricular dysfunction, comorbidities, life expectancy, risk‑benefit balance, and patient preferences. 14, 15
• In surgically eligible patients with multivessel disease and left‑ventricular ejection fraction ≤ 35 %, coronary artery bypass grafting (CABG) is recommended over medical therapy alone to improve long‑term survival. 15

Choice of Revascularization Modality

• For patients at low surgical risk with significant left‑main coronary stenosis, CABG is preferred over medical therapy alone and is the overall favored revascularization strategy compared with percutaneous coronary intervention (PCI), owing to lower rates of spontaneous myocardial infarction and repeat revascularization. 14, 15
• When left‑main disease is of low anatomical complexity (SYNTAX score ≤ 22) and PCI can achieve completeness of revascularization comparable to CABG, PCI may be offered as an alternative because of its lower invasiveness and non‑inferior survival. 14
• In complex multivessel disease, a Heart Team discussion—including interventional cardiology, cardiac surgery, and non‑interventional cardiology representatives—is mandatory to select the optimal treatment strategy and improve outcomes. 14, 15
• The SYNTAX score should be calculated to assess anatomical complexity of multivessel obstructive disease. 15
• The STS (Society of Thoracic Surgeons) score should be calculated to estimate in‑hospital morbidity and 30‑day mortality after CABG. 15

Procedural Guidance for PCI

• Intracoronary imaging (intravascular ultrasound or optical coherence tomography) is mandatory when performing PCI on anatomically complex lesions, particularly left‑main stem, true bifurcations, and long lesions. 14, 15
• Intracoronary pressure measurement (fractional flow reserve, instantaneous wave‑free ratio, or quantitative flow ratio) is mandatory to guide lesion selection for intervention in patients with multivessel disease. 14, 15
• Post‑procedural FFR or iFR assessment should be considered to identify patients at high risk of persistent angina and subsequent clinical events. 14

Evidence‑Based Pharmacologic Management of Coronary Artery Disease

Antiplatelet Therapy

• Aspirin 75–100 mg daily should be prescribed to every adult with coronary artery disease to lower the risk of myocardial infarction and death. 16
• When aspirin is absolutely contraindicated, clopidogrel 75 mg daily is the recommended alternative antiplatelet agent. [16][17]
• Dipyridamole must be avoided because it can aggravate exercise‑induced myocardial ischemia. 17

Lipid‑Lowering Therapy

• Initiate high‑intensity statin therapy immediately in all patients with coronary artery disease to reduce major vascular events and overall mortality. 17

Renin‑Angiotensin System Inhibition

• ACE inhibitors are indicated for every patient with coronary artery disease, providing added benefit when hypertension, diabetes, heart failure, or left‑ventricular dysfunction are present. 16

Beta‑Blocker Therapy

• Beta‑blockers are a first‑line treatment for coronary artery disease, particularly in individuals with a prior myocardial infarction. [16][17]
• In this population, beta‑blockers reduce subsequent cardiac events, help control heart rate, and relieve angina symptoms. 16
• Diabetes does not contraindicate beta‑blocker use; diabetic patients experience equal or greater benefit compared with non‑diabetic patients. 17

Short‑Acting Nitrates for Symptom Relief

• All patients with coronary artery disease should receive sublingual nitroglycerin (or nitroglycerin spray) for rapid relief of effort‑induced angina. 16

Long‑Acting Anti‑Anginal Agents

• Long‑acting calcium‑channel blockers are appropriate when beta‑blockers are contraindicated or poorly tolerated. 16
• When beta‑blocker monotherapy fails to control symptoms, a long‑acting calcium‑channel blocker or a long‑acting nitrate may be added. 16
• Long‑acting calcium‑channel blockers are generally preferred over long‑acting nitrates for maintenance therapy because they provide sustained 24‑hour anti‑ischemic effects. 16

Critical Pitfalls to Avoid

• Do not withhold beta‑blockers in diabetic patients; they obtain equal or greater therapeutic benefit. 17
• Do not use immediate‑release or short‑acting dihydropyridine calcium antagonists, as they increase adverse cardiac events. 16
• Do not use dipyridamole, which can worsen myocardial ischemia. 17
• Do not employ chelation therapy for coronary artery disease, as it lacks proven benefit. 16